文献速递甲状腺疾病

安罗替尼联合信迪利单抗治疗BRAFV600E阴性未分化甲状腺癌的2期试验

Anlotinib Plus Sintilimab for BRAFV600E Negative Unresectable or Metastatic Anaplastic Thyroid Carcinoma: A Single-Center, Single-Arm, Phase 2 Trial.
PubMed 文献 · Thyroid · 2026-01-24

这项单中心、单臂2期试验纳入21例BRAFV600E阴性不可切除或转移性未分化甲状腺癌患者,接受安罗替尼联合信迪利单抗治疗。客观缓解率为47.6%(10/21),疾病控制率为85.7%(18/21),中位无进展生存期为9.63个月。安全性总体可控,3级不良事件发生率为19.0%(4/21)。

要点

  • 安罗替尼联合信迪利单抗在BRAFV600E阴性ATC中ORR达47.6%,DCR达85.7%。
  • 中位PFS为9.63个月,中性粒细胞-淋巴细胞比值较低者PFS更长。
  • 3级不良事件发生率19.0%,常见为AST/ALT升高,安全性总体可控。

核心结论

  • 安罗替尼联合信迪利单抗在BRAFV600E阴性不可切除或转移性ATC中显示出良好疗效和可控安全性。

研究设计与样本

  • 单中心、单臂2期试验,纳入21例BRAFV600E阴性不可切除或转移性ATC患者。
  • 安罗替尼12 mg口服每日一次,每21天周期第1-14天给药;信迪利单抗200 mg静脉输注第1天给药。
  • 主要终点为研究者评估的客观缓解率。

主要发现

  • 1例(4.8%)达完全缓解,9例(42.9%)达部分缓解。
  • 客观缓解率为47.6%(10/21),疾病控制率为85.7%(18/21)。
  • 中位随访9.97个月(CI 6.10至NA),中位无进展生存期为9.63个月(CI 4.03至NA)。
  • 中性粒细胞-淋巴细胞比值<3.06者中位PFS为18.43个月对3.67个月(p=0.010);<5者为14.23个月对2.67个月(p=0.002)。
  • 中位总生存期未达到(CI 13.90至NA),15例(71.4%)患者仍存活。

关键数值与推荐

  • 不良事件发生于66.7%(14/21)患者,3级不良事件发生率为19.0%(4/21)。
  • 最常见不良事件为天冬氨酸氨基转移酶升高(6/21,28.6%)和丙氨酸氨基转移酶升高(5/21,23.8%)。
  • 3级免疫相关不良事件发生于3例患者,包括AST/ALT升高、腹泻、高血压和高甘油三酯血症。

临床怎么用

  • 对于BRAFV600E阴性不可切除或转移性ATC,安罗替尼联合信迪利单抗可作为候选治疗方案。
  • 治疗期间需监测肝功能、血压、血脂及免疫相关不良事件。
  • 中性粒细胞-淋巴细胞比值较低者可能从该联合治疗中获益更多。

局限性

  • 单中心、单臂设计,样本量较小(21例),结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy. Dabrafenib plus trametinib has shown efficacy in BRAFV600E-mutant ATC, but effective therapies remain limited for patients without this mutation. This study aimed to evaluate the efficacy and safety of anlotinib plus sintilimab in BRAFV600E-negative ATC. METHODS: In this phase 2 trial, patients with BRAFV600E-negative unresectable or metastatic ATC received anlotinib (12 mg orally once daily on days 1-14 of a 21-day cycle) plus sintilimab (200 mg intravenously on day 1). The primary endpoint was investigator-assessed objective response rate (ORR). This study is registered at www.chictr.org.cn, ChiCTR2200067045. RESULTS: From December 27, 2022, to June 11, 2025, 21 patients were enrolled. One (4.8%) patient achieved complete response, and nine (42.9%) patients achieved partial response. The ORR and disease control rate were 47.6% (10/21) and 85.7% (18/21), respectively. After median follow-up of 9.97 months (confidence interval [CI] 6.10 to NA), 61.9% (13/21) of patients had discontinued treatment, mainly due to disease progression (7/21, 33.3%), adverse events (AEs) (2/21, 9.5%), and other reasons (4/21, 19.0%). Median progression-free survival (PFS) was 9.63 months (CI 4.03 to NA), with eight (38.1%) patients were still on treatment. Subgroup analysis showed longer PFS in patients with neutrophil-lymphocyte ratio <3.06 (18.43 vs. 3.67 months; p = 0.010) and <5 (14.23 vs. 2.67 months; p = 0.002). Median overall survival was not reached (CI 13.90 to NA), 15 (71.4%) patients remained alive. AEs occurred in 66.7% (14/21) of patients, including grade 3 AEs in 19.0% (4/21). The most common were aspartate aminotransferase (AST) increased (6/21, 28.6%) and alanine aminotransferase (ALT) increased (5/21, 23.8%). Grade 3 immune-related AEs occurred in three patients, including AST/ALT increased, diarrhea, hypertension, and hypertriglyceridemia. CONCLUSIONS: Anlotinib plus sintilimab showed favorable efficacy and manageable safety in BRAFV600E-negative unresectable or metastatic ATC, supporting further investigation.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Gui L, Zhu H, Tang L, et al. Anlotinib Plus Sintilimab for BRAFV600E Negative Unresectable or Metastatic Anaplastic Thyroid Carcinoma: A Single-Center, Single-Arm, Phase 2 Trial. Thyroid. 2026. PMID: 41579120. doi:10.1177/10507256261416838

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。